NO.1 PHARMACY(SH:600833)2021-10-29 16:00Financial Performance - The company's operating revenue for Q3 2021 was ¥364,802,049.26, representing an increase of 8.34% compared to the same period last year[5]. - The net profit attributable to shareholders for Q3 2021 was ¥10,015,006.02, a decrease of 58.97% year-on-year[5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2021 was ¥1,597,503.33, down 80.50% from the previous year[5]. - The basic earnings per share for Q3 2021 was ¥0.0449, a decline of 58.96% compared to the same period last year[6]. - The net profit attributable to shareholders for the year-to-date period was ¥35,965,835.31, down 37.64% compared to the same period last year[5]. - Total operating revenue for the first three quarters of 2021 was CNY 996,659,724.28, a decrease of 16.5% compared to CNY 1,194,693,121.84 in the same period of 2020[20]. - Net profit for the third quarter of 2021 was CNY 35,965,835.31, a decline of 37.6% from CNY 57,677,849.44 in the same quarter of 2020[22]. - The company reported a total comprehensive income of CNY 27,177,944.37 for the third quarter of 2021, compared to CNY 42,949,528.71 in the same quarter of 2020[23]. Cash Flow and Assets - The cash flow from operating activities for the year-to-date period was ¥27,317,271.41, reflecting a decrease of 38.74%[6]. - The company's cash and cash equivalents as of September 30, 2021, were ¥252,428,485.18, down from ¥509,431,257.61 at the end of 2020[17]. - Total assets at the end of the reporting period were ¥1,258,748,964.61, down 9.85% from the end of the previous year[6]. - Total assets as of the end of the third quarter of 2021 amounted to CNY 1,258,748,964.61, compared to CNY 1,396,255,792.15 at the end of the previous year[19]. - Cash inflow from operating activities for the first three quarters of 2021 was CNY 1,078,526,504.03, a decrease of 22.3% compared to CNY 1,387,426,641.04 in the same period of 2020[24]. - Cash and cash equivalents at the end of Q3 2021 stood at CNY 252,128,485.18, a decrease from CNY 671,948,844.06 at the end of Q3 2020[25]. - Total liabilities decreased to CNY 505,318,438.02 in the third quarter of 2021 from CNY 646,939,073.40 in the same period of 2020[19]. Business Operations and Strategy - The decrease in net profit was primarily due to lower sales of civilian epidemic prevention materials and the absence of pandemic-related subsidies received in the previous year[9]. - The company is focusing on expanding its retail and wholesale pharmaceutical business, enhancing local coverage and service quality[15]. - Strategic partnerships with major e-commerce platforms like Alibaba Health and JD Daojia are being pursued to boost online sales[15]. - The company is actively developing DTP pharmacies to capture prescription drug market share[15]. - Employee training programs are being implemented to improve professional skills and drive sales growth in non-pharmaceutical categories[15]. - The company has not reported any changes in its main business operations during the reporting period[14]. Shareholder Information - Total number of common shareholders at the end of the reporting period was 22,991[12]. - The largest shareholder, Bailian Group Co., Ltd., holds 100,274,734 shares, accounting for 44.95% of total shares[12]. Liabilities and Equity - The total liabilities amounted to 646,939,073.40, with a total equity of 749,316,718.75, resulting in total assets of 1,396,255,792.15[29]. - The company reported a decrease in undistributed profits by 1,835,757.61, bringing the total to 290,683,486.98[29]. - The total non-current liabilities reached 121,064,792.99, which includes deferred income of 12,404,932.68 and deferred tax liabilities of 36,457,908.45[29]. - The capital reserve stood at 65,189,347.33, contributing to the overall equity structure[29]. - The company's total equity attributable to shareholders was 742,309,402.86, reflecting a slight decrease of 1,870,933.56[29]. - The total deferred income tax liabilities were reported at 36,457,908.45, highlighting the company's tax obligations[29].